Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:7/1/2008

in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities, whether the Company will be able to complete any potential strategic transaction on terms acceptable to the Company's stockholders, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended March 31, 2008 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isis Pharmaceuticals Conference Call Notice
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
6. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
7. Pharmasset Receives Notice of Allowance
8. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
9. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- ScriptPro has been ... under its Common Security Framework (CSF). According to ... Privacy Manager, "We appreciate this rigorous, top-to-bottom audit. ... that this certification signifies. Our business partners need ... THE CSF CERTIFICATION PROCESS: ScriptPro,s internal security processes ...
(Date:8/21/2014)... BreedIT Corp., (OTCQB: BRDT) ... worldwide license holder and distributor of highly sophisticated ... today is pleased to announce the formation of ... a leading Israeli medical Cannabis breeder. ... breeds of medical Cannabis to meet the requests ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... SAN DIEGO, Jan. 11 CareFusion (NYSE: CFN ... the Food and Drug Administration (FDA) has given the company ... SE line of infusion pumps (also known as the Signature ... Medical Products division of Cardinal Health, has been operating under ...
... , PRINCETON, N.J., Jan. 11 Covance ... present at the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, ... a live webcast of the presentation at www.covance.com . ... on 10 minutes early. , Covance, with headquarters in Princeton, New ...
Cached Medicine Technology:FDA Lifts Injunction on Manufacture and Sale of CareFusion Alaris(R) SE Pump 2
(Date:8/22/2014)... 2014 The first ORTC Public ... Microsoft, and Google. ( http://ortc.org/wp-content/uploads/2014/08/ortc.html ) , ... to create a WebRTC 1.1 API with exceptional ... WebRTC, ORTC (Object Real-time Communication) enables plugin-free real-time ... specifically tailored to provide the direct control needed ...
(Date:8/22/2014)... 22, 2014 The Berkowitz Law Firm ... a client who suffered severe, permanent injuries in an ... driver (docket number FST-CV13-6018309-S). The case was pending in ... According to Jennifer Amdur of The Berkowitz Law Firm ... all of whom were allegedly injured following ...
(Date:8/22/2014)... FastFingerprints is adding a new location to ... Wednesday, August 27, 2014 and is located at 3740 ... the addition of this new office, that will bring ... Cleveland area. Our new Cleveland-Midtown location will provide ... hours of operation will be Monday-Friday 8:00am – 5:00pm ...
(Date:8/22/2014)... 22, 2014 Teen substance abuse has ... OH. Unfortunately, most young adults never receive the professional ... the community, the new Troubled Teens Columbus helpline was ... to overcome their drug and alcohol dependencies . ... teens and their parents can speak directly to a ...
(Date:8/22/2014)... 2014 Dr Murray Grossan was interviewed for ... , In the October 2014 issue of Bottom Line Personal ... his method of treating snoring, and in some cases Obstructive ... half of all adults snore occasionally, and about 25% do ... air passages in the back of the throat tend to ...
Breaking Medicine News(10 mins):Health News:Hookflash, Google and Microsoft lead on ORTC / WebRTC 1.1 Public Draft 2Health News:Hookflash, Google and Microsoft lead on ORTC / WebRTC 1.1 Public Draft 3Health News:The Berkowitz Law Firm LLC Reaches a $2 Million Settlement for a Client Allegedly Injured in Drunk Driving Accident 2Health News:FastFingerprints Expands In The Cleveland Ohio Area 2Health News:FastFingerprints Expands In The Cleveland Ohio Area 3Health News:New Helpline in Columbus Assists Troubled Teen Find Youth Rehab 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 3
... VNDA ) ("Vanda" or the "Company") announced today ... contest by withdrawing its nominations of director candidates for election ... liquidate the Company. TCP had previously notified the Company of ... of its candidates to the Vanda Board at the Company,s ...
... is National Lupus Awareness MonthWASHINGTON, May 7 ... risks associated with breast cancer and heart disease, but ... aware of another potentially fatal disease that disproportionately strikes ... The disease is lupus.Although more than 1.5 million ...
... May 7 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. ("China Pharma") ... pharmaceutical products in China, today,announced that it plans to ... 2009, before the market opens. , ... 8:00 am ET on May 15, 2009 to,discuss fiscal ...
... (NYSE: MTD ) today announced the webcast of its ... Conference in New York on Thursday, May 14, 2009, at 10:40 ... presentation, visit the investor relations page on the Company,s Web site ... /investors . A replay of the webcast will be ...
... Recent scientific studies published in the medical journals ... Journal of Nutrition, and others, showed that the ... anti-cancer activities. Gene-Eden is a dietary supplement ... unique, patent-pending formulation. Gene-Eden was introduced in February ...
... Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on ... results for the three month period ended March 31, 2009. ... in the first quarter of 2008. The net loss for ... diluted share, compared to a net loss of $762,000, or ...
Cached Medicine News:Health News:Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital 2Health News:Public Lacks Awareness of Serious Disease With Life-Threatening Complications 2Health News:Public Lacks Awareness of Serious Disease With Life-Threatening Complications 3Health News:China Pharma Holdings, Inc. to Report First Quarter 2009 Financial Results on May 15, 2009 2Health News:The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde 2Health News:PLC Systems Reports First Quarter 2009 Results 2Health News:PLC Systems Reports First Quarter 2009 Results 3Health News:PLC Systems Reports First Quarter 2009 Results 4Health News:PLC Systems Reports First Quarter 2009 Results 5
Standard Deflectable Catheters...
The Explorer ST "soft tip" catheter has a proximal shaft with a soft tip. It is available in both a 5F and 6F shaft configuration....
... offers a wide range of deflectable curve ... needs of children and other patients with ... demanding specifications using only the finest materials. ... wire braiding and extrusion technologies results in ...
A-Focus I & II Catheters. A-Focus steerable atrial mapping catheter. Available in 10, 12, 14 and 20 electrode configurations. (Shown with 14 electrodes)....
Medicine Products: